definiens: shall mean such Antibody Technology Controlled by ABX or itsAffiliates that is Reasonably Necessary to complete the following portions of a Research Program generally inaccordance with the template Research Program Work Plan attached hereto, that has as its goal the delivery ofAntibodies that meet the applicable CDTP criteria in accordance with industry standards : ( a ) the immunization ofXenoMouse Animals, ( b ) the generation of Antibodies from such XenoMouse Animals, and ( c ) the initialcharacterization of such Antibodies ( consisting of binding such Antibodies to an antigen ( by ELISA and FACS),[Confidential treatment requested ] ; in each case as customarily practiced by ABX, utilizing ABX standard techniquesand materials ( other than transfer vectors proprietary from Third Parties ) for hybridoma or XenoMax Technologyapproaches